| Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma B Koneru, G Lopez, A Farooqi, KL Conkrite, TH Nguyen, SJ Macha, ... Cancer research 80 (12), 2663-2675, 2020 | 68 | 2020 |
| ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156 B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger, ... Science translational medicine 13 (607), eabd5750, 2021 | 39 | 2021 |
| Reactive oxygen species–mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies MR Makena, B Koneru, TH Nguyen, MH Kang, CP Reynolds Molecular cancer therapeutics 16 (4), 649-661, 2017 | 37 | 2017 |
| Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2–expressing neuroblastoma preclinical models TH Nguyen, B Koneru, SJ Wei, WH Chen, MR Makena, E Urias, MH Kang, ... Molecular cancer therapeutics 18 (12), 2270-2282, 2019 | 18 | 2019 |
| Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia MM Song, MR Makena, A Hindle, B Koneru, TH Nguyen, DU Verlekar, ... Anti-Cancer Drugs 30 (2), 117-127, 2019 | 13 | 2019 |
| Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies MR Makena, TH Nguyen, B Koneru, A Hindle, WH Chen, DU Verlekar, ... Anti-Cancer Drugs 32 (1), 34-43, 2021 | 11* | 2021 |
| Biosynthesis of zinc nanoparticles by Aspergillus species KV Pavani, K Balakrishna, NK Cheemarla Int. J. Nanotechnol. Appl 5 (1), 27-36, 2011 | 11 | 2011 |
| Alternative lengthening of telomeres in cancer confers a vulnerability to reactivation of p53 function SJ Macha, B Koneru, TA Burrow, C Zhu, D Savitski, RL Rahman, ... Cancer research 82 (18), 3345-3358, 2022 | 9 | 2022 |
| Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines MR Makena, HE Cho, TH Nguyen, B Koneru, DU Verlekar, A Hindle, ... Pediatric blood & cancer 65 (12), e27447, 2018 | 6 | 2018 |
| The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide+ irinotecan against models of high-risk neuroblastoma A Hindle, B Koneru, MR Makena, L Lopez-Barcons, WH Chen, ... Anti-cancer drugs 32 (3), 233-247, 2021 | 5 | 2021 |
| Comparison of the cytotoxicity and increase of reactive oxygen species and dihydroceramides of fenretinide to its major metabolites (4-oxo-and 4-methoxyphenyl fenretinide) in T … MM Song, MR Makena, A Hindle, B Koneru, TH Nguyen, H Cho, ... Cancer Research 75 (15_Supplement), 2616-2616, 2015 | 3 | 2015 |
| ALT Neuroblastoma Chemoresistance due to ATM Activation by Telomere Dysfunction is Reversible with the ATM Inhibitor AZD0156 B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger, ... bioRxiv, 2021.04. 06.438692, 2021 | 1 | 2021 |
| Prevalence of Alternative Lengthening of Telomeres (ALT) in Pediatric Sarcomas Determined by the Telomeric DNA C-circle Assay CP Reynolds, TA Burrow, B Koneru, SJ Macha, W Sun, F Barr, T Triche Authorea Preprints, 2024 | | 2024 |
| Compositions and methods for the diagnosis and treatment of ALT cancer CP Reynolds, B Koneru, S Macha US Patent 11,913,077, 2024 | | 2024 |
| INHIBITION OF ATM KINASE BY THE CNS-PENETRANT AZD1390 ENHANCED RADIOTHERAPY IN NEUROBLASTOMA AND RHABDOMYOSARCOMA PRECLINICAL MODELS T Burrow, K Graham, B Koneru, A Farooqi, P Houghton, F Dela Cruz, ... PEDIATRIC BLOOD & CANCER 70, S69-S69, 2023 | | 2023 |
| APR-246, which restores p53 function, is highly active against alternative lengthening of telomere (ALT) cell lines and PDXs SJ Macha, B Koneru, T Burrow, C Zhu, D Savitski, J Nance, K McCoy, ... Cancer Research 82 (12_Supplement), 6228-6228, 2022 | | 2022 |
| Cytotoxic Activity of Difluoromethylornithine Compared with Fenretinide in Neuroblastoma Cell Lines M Makena, H Cho, T Nguyen, B Koneru, D Verlekar, A Hindle, ... PEDIATRIC BLOOD & CANCER 64, S235-S235, 2017 | | 2017 |
| MGMT Inhibitor O6-Benzylguanine Enhanced the Activity of Temozolomide plus Irinotecan against in Vitro and in Vivo Models of Progressive Disease High-Risk Neuroblastoma A Hindle, M Makena, B Koneru, T Nguyen, WH Chen, CP Reynolds PEDIATRIC BLOOD & CANCER 64, S122-S122, 2017 | | 2017 |
| Increased DNA repair capacities and p53/MDM2 pathway aberrations hallmark neuroblastoma cell lines with the alternative lengthening of telomeres (ALT) phenotype. A Farooqi, A Hindle, B Koneru, J Shay, P Reynolds Cancer Research 73 (8_Supplement), 580-580, 2013 | | 2013 |
| atm inhiBition sensitizes alt neuroBlastomas to chemotherapy B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger | | |
C Patrick ReynoldsCancer Center Director, TTUHSC School of MedicineVerified email at ttuhsc.edu
